REGENXBIO Inc (Nasdaq: RGNX), clinical-stage biotechnology company, announced its financial results for 2019 on Wednesday.
The company reported revenues of USD35.2m in 2019 compared to USD218.5m in 2018.
The firm posted research and development expenses at USD124.2m in 2019 compared to USD83.9m in 2018.
Net loss was USD94.7m, or USD2.58 basic and diluted net loss per share, for the year ended 31 December 2019, compared to net income of USD99.9m, or USD2.99 basic and USD2.73 diluted net income per share, for the year ended 31 December 2018.
'In 2020, we are broadening our internal gene therapy pipeline using our proprietary NAV Technology Platform, and advancing key programs including RGX-314 for the treatment of retinal diseases,' said Kenneth T Mills, president and chief executive officer of REGENXBIO. 'As we drive the RGX-314 program forward with new trials in wet AMD and diabetic retinopathy planned for later this year, we are also advancing our RGX-121 program in MPS II based on encouraging data from the first cohort of patients. We are pleased with the advancement of the RGX-111 and RGX-501 programs, and look forward to submitting an IND for RGX-181 and providing updates for our research programs in HAE and neurodegenerative diseases later this year.'
Anixa Biosciences and Curia to finalise formulation of breast cancer vaccine for Phase 2 trial
Akagera Medicines receives Gates Foundation grant expansion to advance tuberculosis vaccine
Ten63 Therapeutics launches BEYOND-Alpha early adopter programme
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Rakuten Medical launches Phase 1 first-in-human trial of PD-L1-targeted RM-0256 photoimmunotherapy
BioArctic and Eisai report positive five-year data for Leqembi in early Alzheimer's disease
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer